Blog
RSS FeedPosted by Michael Wonder on 04 Oct 2018
NICE publishes draft guidance for idelalisib
4 October 2018 - The Department of Health and Social Care has asked the NICE to produce guidance on using idelalisib ...
Posted by Michael Wonder on 03 Oct 2018
Preliminary NICE ‘no’ for Takeda’s Alunbrig
3 October 2018 - Draft guidelines from the NICE do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig. ...
Posted by Michael Wonder on 19 Sep 2018
NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma
19 September 2018 - The National Institute for Health and Care Excellence has turned down NHS funding for use of ...
Posted by Michael Wonder on 19 Sep 2018
NICE encourages further discussions on Kymriah for adult lymphoma
19 September 2018 - CAR-T is too expensive to recommend as a treatment for adults with lymphoma, NICE says in draft ...
Posted by Michael Wonder on 17 Sep 2018
Targeted treatment for melanoma to be free on NHS
17 Septembre 2018 - Hundreds of patients with a type of aggressive skin cancer will be offered a targeted therapy ...
Posted by Michael Wonder on 17 Sep 2018
Patients with high-risk skin cancer have new treatment option
17 September 2018 - Hundreds of patients with a type of advanced skin cancer are set to benefit from a new ...
Posted by Michael Wonder on 13 Sep 2018
DoH moves to ensure equal access to cancer drugs in Northern Ireland
13 September 2018 - The Department of Health in Northern Ireland has unveiled plans to boost access to innovative new ...
Posted by Michael Wonder on 10 Sep 2018
NICE turns down Opdivo for adjuvant melanoma therapy
10 September 2018 - BMS drug currently only licensed treatment in this setting. ...
Posted by Michael Wonder on 05 Sep 2018
Deal for NHS to offer exciting new child cancer therapy
5 September 2018 - A deal has been struck to let the NHS offer children an expensive new cancer therapy ...
Posted by Michael Wonder on 04 Sep 2018
Merck gets partial thumbs-down on Keytruda in lymphoma from NICE cost-effectiveness watchdogs
4 September 2018 - NICE quibbled with Merck's methodology for demonstrating the cost effectiveness of Keytruda in treating Hodgkin lymphoma patients ...
Posted by Michael Wonder on 29 Aug 2018
Cancer charities dismayed after ‘new generation’ therapy rejected as too expensive
29 August 2018 - A NICE committee said the cost of the drug was “too high for it to be considered ...
Posted by Michael Wonder on 28 Aug 2018
Cabometyx gets NICE recommendation in renal cell carcinoma
24 August 2018 - French drugmaker Ipsen that it has received a recommendation from NICE for National Health Service funding ...
Posted by Michael Wonder on 23 Aug 2018
NICE publishes preliminary guidance on new combo product for AML
23 August 2018 - The Department of Health and Social Care has asked NICE to produce guidance on using liposomal cytarabine ...
Posted by Michael Wonder on 23 Aug 2018
NICE publishes final guidance for dinutuximab
22 August 2018 - Dinutuximab is used to treat children with brain cancer. ...
Posted by Michael Wonder on 17 Aug 2018
NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery
17 August 2018 - NICE is sticking with its position that Roche’s Perjeta is not cost-effective enough to be used ...